ActiveGRANT

DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award

Name: DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award
Creator: Department of Defense
Keywords: GRANT

Department of DefenseDefense Health Agency Contracting Activity - DHACA

AI Overview

Develop ALS therapeutics from preclinical validation through FDA IND-enabling studies. This award accelerates drug candidates toward clinical testing while requiring parallel development of mechanism-specific biomarkers for improved patient selection and trial design.

This summary is AI-generated from the official solicitation.

Key Details

Agency

Department of Defense

Funding Amount

Up to $12,000,000

Release Date

May 4, 2026

Due Date

September 30, 2026

Official Description

<p><strong>Summary: </strong>The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited amyotrophic lateral sclerosis (ALS) experience are strongly encouraged to in...

View on official source

Change History

Date ChangedJul 29, 2026 at 9:06 PM